Breaking News Instant updates and real-time market news.

AVRO

AvroBio

$38.85

3.2 (8.98%)

08:06
08/09/18
08/09
08:06
08/09/18
08:06

AvroBio reports Q2 EPS ($2.98), consensus (47c)

AvroBio said the increase in net loss for the year was due to increased research and development expenses, as well as an increase in general and administrative expenses primarily related to investments in the company's infrastructure in preparation for becoming a publicly traded company. AvroBio ended the quarter with $155M in cash. Based on its current operating plan, the company expects its cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements into 2020. It said, "2018 has been a very productive year thus far for AVROBIO. We successfully completed a Series B financing and a successful initial public offering which positions us well to achieve our mission of advancing our pipeline of gene therapies to cure rare diseases in a single dose. Our main focus is on the patients, and I am pleased with the progress we have made with our lead program, AVR-RD-01 in Fabry disease. In June, we completed the enrollment of the first patient in our Phase 2 clinical trial, and even more recently, the third patient was enrolled in our ongoing investigator-sponsored Phase 1 clinical trial."

  • 14

    Aug

AVRO AvroBio
$38.85

3.2 (8.98%)

07/16/18
WEDB
07/16/18
INITIATION
Target $38
WEDB
Outperform
AvroBio initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started AvroBio with an Outperform rating and $38 price target as he believes the shares could have significant upside given that its gene therapy platform is developing potentially curative therapies for rare lysosomal storage diseases that are poorly controlled on current treatments.
07/16/18
MSCO
07/16/18
INITIATION
Target $37
MSCO
Overweight
AvroBio initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated AvroBio (AVRO) with an Overweight rating and $37 price target, noting that its a unique gene therapy company that has human clinical data for one of its programs at the time of its initial public offering. He points to Novartis' (NVS) recent acquisition of AveXis for $8.7B, or an 88% premium, as an illustration of the substantial interest in and valuation premium put into many names in the gene therapy space.
07/16/18
COWN
07/16/18
INITIATION
COWN
Outperform
AvroBio initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated AvroBio with an Outperform rating citing its four programs that have been generated from its lentiviral gene therapy platform for lysomal storage diseases. The analyst expects the company to create long-term value with its gene therapy programs.
07/16/18
WELS
07/16/18
INITIATION
Target $40
WELS
Outperform
AvroBio initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started AvroBio with an Outperform rating and $40 price target based on what he views as a differentiated capability in applying lentiviral-based gene therapy, a proven platform with curative potential, to lysosomal storage diseases, proof-of-mechanism afforded by existing LSD treatment approaches including enzyme replacement therapy and allogeneic hematopoietic stem cell transplant, encouraging initial phase 1 data in Fabry disease demonstrating rapid, robust, and sustained enzyme expression, and a leverageable platform that extends to multiple LSDs with established markets and multibillion dollar opportunities.

TODAY'S FREE FLY STORIES

MSFT

Microsoft

$113.66

-1.04 (-0.91%)

, ADBE

Adobe

$261.32

0.47 (0.18%)

11:09
09/24/18
09/24
11:09
09/24/18
11:09
Hot Stocks
Microsoft, Adobe, SAP announce Open Data Initiative »

The CEOs of Adobe (ADBE),…

MSFT

Microsoft

$113.66

-1.04 (-0.91%)

ADBE

Adobe

$261.32

0.47 (0.18%)

SAP

SAP

$122.23

0.59 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Nov

  • 03

    Mar

FCX

Freeport McMoRan

$14.38

-0.22 (-1.51%)

11:05
09/24/18
09/24
11:05
09/24/18
11:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:05
09/24/18
09/24
11:05
09/24/18
11:05
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

MCD

McDonald's

$163.93

-0.23 (-0.14%)

11:02
09/24/18
09/24
11:02
09/24/18
11:02
Hot Stocks
McDonald's International Lead Markets & Chief Restaurant Officer Goare to retire »

McDonald's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$290.57

-1.46 (-0.50%)

11:01
09/24/18
09/24
11:01
09/24/18
11:01
Periodicals
White House accepts Rod Rosenstein's resignation, Bloomberg reports »

Following an Axios report…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$290.57

-1.46 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
09/24/18
09/24
11:00
09/24/18
11:00
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NTR

Nutrien

$57.09

-0.15 (-0.26%)

10:58
09/24/18
09/24
10:58
09/24/18
10:58
Hot Stocks
Nutrien announces Jochen Tilk will step down as Executive Chair »

Nutrien announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

NTNX

Nutanix

$43.00

-3.55 (-7.63%)

, MSFT

Microsoft

$113.86

-0.84 (-0.73%)

10:56
09/24/18
09/24
10:56
09/24/18
10:56
Downgrade
Nutanix, Microsoft, VMware rating change  »

Nutanix downgraded to…

NTNX

Nutanix

$43.00

-3.55 (-7.63%)

MSFT

Microsoft

$113.86

-0.84 (-0.73%)

VMW

VMware

$153.86

1.86 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 10

    Oct

  • 11

    Oct

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Nov

  • 06

    Dec

  • 10

    Dec

  • 03

    Mar

IONS

Ionis Pharmaceuticals

$50.45

1.34 (2.73%)

, ALNY

Alnylam

$92.42

-2.17 (-2.29%)

10:56
09/24/18
09/24
10:56
09/24/18
10:56
Recommendations
Ionis Pharmaceuticals, Alnylam analyst commentary  »

Ionis platelet issue now…

IONS

Ionis Pharmaceuticals

$50.45

1.34 (2.73%)

ALNY

Alnylam

$92.42

-2.17 (-2.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 06

    Oct

  • 27

    Nov

10:55
09/24/18
09/24
10:55
09/24/18
10:55
General news
Treasury Action: yields reverted lower »

Treasury Action: yields…

TRU

TransUnion

$74.19

-0.11 (-0.15%)

10:50
09/24/18
09/24
10:50
09/24/18
10:50
Options
Notable call write in TransUnion »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 21

    Oct

  • 23

    Oct

10:50
09/24/18
09/24
10:50
09/24/18
10:50
General news
U.S. Dallas Fed manufacturing index dropped 2.8 points to 28.1 in September »

U.S. Dallas Fed…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$290.74

-1.29 (-0.44%)

10:46
09/24/18
09/24
10:46
09/24/18
10:46
Technical Analysis
Technical Take: SPDR S&P 500 ETF nears session lows »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$290.74

-1.29 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$9.43

0.35 (3.85%)

, SIRI

Sirius XM

$6.55

-0.425 (-6.10%)

10:45
09/24/18
09/24
10:45
09/24/18
10:45
Downgrade
Pandora, Sirius XM rating change  »

Pandora downgraded to…

P

Pandora

$9.43

0.35 (3.85%)

SIRI

Sirius XM

$6.55

-0.425 (-6.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

10:45
09/24/18
09/24
10:45
09/24/18
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

NBIX

Neurocrine

$121.55

1.7 (1.42%)

10:45
09/24/18
09/24
10:45
09/24/18
10:45
Conference/Events
Neurocrine has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$291.02

-1.01 (-0.35%)

10:40
09/24/18
09/24
10:40
09/24/18
10:40
Periodicals
Deputy AG Rod Rosenstein verbally resigns to John Kelly, Axios reports »

Deputy Attorney General…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$291.02

-1.01 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLF

Cleveland-Cliffs

$12.47

0.31 (2.55%)

10:40
09/24/18
09/24
10:40
09/24/18
10:40
Options
Cleveland Cliffs calls active as shares move to 52-week highs »

Cleveland Cliffs calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

AMEH

Apollo Medical

$17.73

1.11 (6.68%)

10:39
09/24/18
09/24
10:39
09/24/18
10:39
Hot Stocks
Breaking Hot Stocks news story on Apollo Medical »

Apollo Medical Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:37
09/24/18
09/24
10:37
09/24/18
10:37
General news
Dallas Fed Mfg Survey General Activity Index data reported »

September Dallas Fed Mfg…

AMEH

Apollo Medical

$17.73

1.11 (6.68%)

10:34
09/24/18
09/24
10:34
09/24/18
10:34
Hot Stocks
Breaking Hot Stocks news story on Apollo Medical »

Apollo Medical Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$10.53

-0.25 (-2.32%)

10:30
09/24/18
09/24
10:30
09/24/18
10:30
Recommendations
Caesars analyst commentary  »

Caesars defended at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$15.20

0.25 (1.67%)

10:30
09/24/18
09/24
10:30
09/24/18
10:30
Options
30K US Oil Fund Oct 14 - 15 call spreads trade at 74c »

30K US Oil Fund Oct 14 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$25.38

-1.1 (-4.15%)

10:25
09/24/18
09/24
10:25
09/24/18
10:25
Hot Stocks
JD.com drops as new WeChat messages emerge following CEO's rape accusations »

Shares of JD.com (JD)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.66

4.69 (3.85%)

10:24
09/24/18
09/24
10:24
09/24/18
10:24
Recommendations
Alexion analyst commentary  »

Piper 'incrementally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 18

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.